Author

Bram G. Verheggen

Observed names: B Verheggen, B. G. Verheggen, B. Verheggen, B.G. Verheggen, BG Verheggen, Bram G Verheggen, Bram Verheggen, Verheggen, B., Verheggen, B.G., Verheggen, Bram G.

Observed institution: Pharmerit (Netherlands)

OpenAlex ID: A5109223880

Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013

2015 · M. Charokopou, F.J. Sabater, et al. · Current Medical Research and Opinion · 44

Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany

2012 · K.Y. Westerhout, B.G. Verheggen, et al. · Journal of Medical Economics · 44

Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass‐allergic rhinoconjunctivitis in Germany

2015 · Bram G Verheggen, Kirsten Y Westerhout, et al. · Clinical and Translational Allergy · 37

Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experiments

2016 · M. Heisen, S. A. Baeten, et al. · Current Medical Research and Opinion · 19

Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective

2016 · L. H. Chuang, B. G. Verheggen, et al. · Journal of Medical Economics · 18

PDF

Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial

2013 · I. M. Majer, H. Gelderblom, et al. · Journal of Medical Economics · 17

PDF

Economic Evaluation of Primary Prevention of Cardiovascular Diseases in Mild Hypertension: A Scenario Analysis for the Netherlands

2014 · Jelena Stevanović, Anouk C. O’Prinsen, et al. · Clinical Therapeutics · 12

Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing–remitting multiple sclerosis in The Netherlands

2012 · M. Heisen, M. J. Treur, et al. · Journal of Medical Economics · 11

PDF

Cost-Effectiveness of Partially Hydrolyzed Whey Protein Formula in the Primary Prevention of Atopic Dermatitis in At-Risk Urban Filipino Infants

2014 · Abhijeet J. Bhanegaonkar, Erica G. Horodniceanu, et al. · Value in Health Regional Issues · 9

Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder

2012 · Bram G. Verheggen, Richard Lee, et al. · Journal of Medical Economics · 9

PDF

Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands

2021 · J. A. Spoorendonk, J.-B. Briere, et al. · Journal of Medical Economics · 7

PDF

Cost-Effectiveness of Nivolumab in Patients with Advanced or Metastatic Renal Cell Carcinoma in Portugal

2016 · K Verleger, AJ Almeida, et al. · Value in Health · 5

Cost-Effectiveness of Exenatide Twice Daily (Bid) Added To Basal Insulin Compared To A Bolus Insulin Add-On In Turkey

2014 · S. Malhan, S. Güler, et al. · Value in Health · 3

Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective

2014 · M. Charokopou, H. Vioix, et al. · Value in Health · 3

Impact of Allergen Immunotherapy on Symptom-Free Days and Health Care Costs in Patients With Grass Pollen-Induced Allergic Rhinitis in Germany

2014 · M. Najib, K.Y. Westerhout, et al. · Value in Health · 3

PDF

Cost-Effectiveness of Ibrutinib in Adult Patients with Relapsed Chronic Lymphocytic Leukaemia in the Netherlands

2016 · H Welten, TJ Ignacio, et al. · Value in Health · 2

PDF

Cost-Effectiveness Analysis of Exenatide Once-Weekly Versus Dulaglutide, Liraglutide and Lixisenatide for the Treatment of Type 2 Diabetes Mellitus: An Analysis from the UK NHS Perspective

2015 · M Charokopou, L Chuang, et al. · Value in Health · 2

The Impact of Long-Term Clinical Evidence on Cost-Effectiveness of Exenatide Once Weekly (Bydureon®) Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus (T2dm) From A Uk Nhs Perspective

2014 · M. Charokopou, H. Vioix, et al. · Value in Health · 2

Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective

2014 · M. Charokopou, H. Vioix, et al. · Value in Health · 2

Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective

2014 · M. Charokopou, H. Vioix, et al. · Value in Health · 2

The Cost-Effectiveness of Dapagliflozin In Combination With Insulin for the Treatment of Type 2 Diabetes Mellitus (T2dm) In Spain

2014 · J. Sánchez-Covisa, M. Capel, et al. · Value in Health · 2

Overview of Health Economic Models in Type 2 Diabetes Mellitus (T2DM); A Systematic Literature Review

2013 · M. Charokopou, F.J. Sabater, et al. · Value in Health · 2

PDF

PRS30 Cost-Effectiveness Analysis of 100% Whey-Based Partially Hydrolyzed Infant Formula Used for Prevention of Atopic Dermatitis in Germany

2012 · E. Erdogan Ciftci, E.G. Horodniceanu, et al. · Value in Health · 2

Pin11 Modeling the Inpatient and Outpatient Costs of Methicillin-resistant Staphyloccocus Aureus (mrsa) Complicated Skin and Soft Tissue Infections (cssti): a Comparison of Linezolid, Vancomycin, Daptomycin, and Tigecycline

2009 · JM Stephens, X Gao, et al. · Value in Health · 2

Efficacy of Recombinant Activated Factor VII (rFVIIa) vs. Activated Prothrombin Complex Concentrate (APCC) in Patients with Hemophilia with Inhibitors: A Bayesian Meta-Analysis.

2007 · Maarten Jacob Treur, Fay McCracken, et al. · Blood · 2

Works count: 58

Citation count: 270

H-index: 9

I10-index: 8